Liftstream is an executive search recruitment company in the life sciences sector
M&A Continues to Dominate the Rare Diseases Landscape
Alexion took everyone by surprise in recent weeks by announcing a very sizable acquisition of Boston-based Synageva for $8.4bn. This was a significant deal which will only serve to strengthen valuations of rare disease biotechnology companies, which continue to be in the M&A cross-hairs of both pharmaceutical and big-biotech companies.
Posted in Orphan Drugs and Rare Diseases
Tagged AbbVie, Actelion, Alexion, bioValley, Boston, Boston Biotech, Flemming Ornskov, M&A, NPS Pharmaceuticals, Orphan Drug, Pfizer, Rare Disease, Shire, SOBI, Swiss, Synageva
Leave a comment
Women Currently only 10% of Biotech Boards, Gender Study Shows
Authored by Karl Simpson
Posted in Executive Appointments, Pharmaceutical business, Recruitment Market
Tagged Bay Area Cluster, biotechnology, Board DIrectors, Boston, Boston Biotech, California, corporate VC, Diversity, europe, executive search, female, Gender, Karl Simpson, leadership, life sciences, Liftstream, male, Massachusetts, non executive directors, NVCA, report, UK, USA, venture capital
Leave a comment
Massachusetts biotech continues to excite with new investments
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Abingworth Management, BioPharma America, Biotechnology cluster, Boston, Brookside Capital, Cristina Csimma, Cydan, David Mott, Deerfield, DELPHI, Dicer Substrate siRNA, Dicerna Pharmaceuticals, drug delivery technologies, Duchenne Muscular Dystrophy, EDI200, Edimer Pharmaceuticals, EnCore™, exon skipping, Exportin-1, Forsite Capital Management, Genzyme, Inhibitors of Nuclear Export, innovation, investors, Karyopharm Therapeutics, Massachusetts, Neil Kirby, New Enterprise Associates, New Leaf Venture Partners, NEZ, Omega Funds, oncology market, Orphan Drug, Prosensa, RA Capital, Rare Disease, Sanofi, Series B, SR One, Third Rock Ventures, TKT, undruggable disease, Vertex Pharmaceuticals, X-linked Hypohidrotic Ectodermal Dysplasia, XLHED
Leave a comment
Roche reaffirms commitment to Hematology Testing
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged anaemia, Bausch & Lomb, blood diseases, Bloodhound, Boston, Boston Biotech cluster, CMI, Constitution Medical Inc, COO, diagnostics, hematology, laboratory solutions, leukaemia, Roche, Roche Diagnostics, Roland Diggelmann, Valeant, Warburg Pincus
Leave a comment
Genesis 2012 – The Debate on UK Biotech
Authored by Karl Simpson
Posted in Pharmaceutical business
Tagged Andrew J Pulkrabek, AstraZeneca, BIA, Biocity, BioLauncher, biotech, Biotech Clusters, BMS, Boston, Bristol-Myers Squibb, Cambridge, CEO, Clusters, Datamonitor, David Phillips, Enablers, genesis 2012, Genesis debate, Glen Crocker, Greer Deal, Industry, Kenneth Powell, King's Health Partners, Life Science, Life Science Investment Organisation, LifeScience Ventures, Liftstream, London, Lubor Gaal, Mark Treherne, Mission Therapeutics, NICE, Oxford, Prof. Sir Robert Lechler, Q-CHIP, Rowan Gardner, Shaun Grady, SR One, Steve Bates, UK, UKBIF
1 Comment